Latest news with #AnnualGeneralandSpecialMeeting
Yahoo
13-06-2025
- Business
- Yahoo
Result of AGM
Reykjavík, June 13, 2025 (GLOBE NEWSWIRE) -- ('Amaroq' or the 'Corporation' or the 'Company') Annual General and Special Meeting ('AGM') Results TORONTO, ONTARIO –13 June, 2025 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation focused on unlocking Greenland's mineral potential, announces the results of voting at its AGM held on June 13, 2025. Shareholders voted in favour of all items put forward at the AGM. AGM Results The following proxy votes for the AGM were received from the shareholders: Motion Description Votes For % Votes Cast Against Withheld/Abstain 1 Election of directors 01 Graham Stewart 65,895,188 77.18% 19,485,220 0 02 Eldur Olafsson 85,381,306 100% 102 0 03 Sigurbjorn Thorkelsson 83,380,232 97.66% 2,001,177 0 04 David Neuhauser 65,892,544 77.17% 19,488,865 0 06 Line Frederiksen 85,380,015 100% 1,393 0 06 Warwick Morley-Jepson 85,377,193 100% 4,215 2 Re-appointment of Auditors 84,234,972 97.68% 0 2,000,802 3 Stock option plan 73,559,019 86.15% 11,822,389 0 4 Restricted Share Unit Plan 56,074,063 65.67% 29,307,345 0 5 Change of Name 86,213,508 99.97% 21,565 0 Enquiries: Amaroq Minerals Olafsson, Executive Director and CEO eo@ Ed Westropp, Head of BD and Corporate Affairs +44 (0)7385755711 ewe@ Eddie Wyvill, Corporate Development+44 (0)7713 126727ew@ Panmure Liberum Limited (Nominated Adviser and Corporate Broker)Scott MathiesonNikhil Varghese+44 (0) 20 7886 2500 Canaccord Genuity Limited (Corporate Broker)James AsensioHarry ReesTel: +44 (0) 20 7523 8000 Camarco (Financial PR)Billy CleggElfie KentFergus Young+44 (0) 20 3757 4980 For Corporation updates:Follow @Amaroq_Minerals on X (Formerly known as Twitter)Follow Amaroq Minerals Ltd. on LinkedIn Further Information: About Amaroq Minerals Amaroq's principal business objectives are the identification, acquisition, exploration, and development of gold and strategic metal properties in South Greenland. The Company's principal asset is a 100% interest in the Nalunaq Gold mine. The Company has a portfolio of gold and strategic metal assets in Southern Greenland covering the two known gold belts in the region as well as advanced exploration projects at Stendalen and the Sava Copper Belt exploring for Strategic metals such as Copper, Nickel, Rare Earths and other minerals. Amaroq Minerals is continued under the Business Corporations Act (Ontario) and wholly owns Nalunaq A/S, incorporated under the Greenland Companies Act. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Inside Information This announcement does not contain inside information.
Associated Press
12-06-2025
- Business
- Associated Press
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the successful completion of its Annual General and Special Meeting ('AGSM'), which was held on Wednesday, June 11 th, 2025, at the Company's head office in Toronto, Ontario, Canada. Following shareholder approval on various resolutions and formal conclusion of the AGSM meeting, Theralase® hosted a virtual corporate presentation via Zoom to provide shareholders with an in-depth overview of the Company's strategic objectives and upcoming milestones for 2025 and 2026. The presentation highlighted current and planned clinical development programs focused on accelerating the commercialization of Theralase®'s innovative therapeutic technologies. For those unable to attend the live virtual session, an archived recording of the presentation can be accessed via the following link: Watch the AGSM Virtual Presentation here: AGSM Virtual Presentation Recording - Presented June 11th, 2025 Theralase® wishes to thank its shareholders and stakeholders for their ongoing support as the Company advances on its mission to commercialize safe and effective therapeutics to destroy various cancers, bacteria and viruses, with minimal impact on healthy tissue. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Yahoo
11-06-2025
- Business
- Yahoo
BlackBerry to hold Annual Meeting of Shareholders on June 25, 2025
WATERLOO, ON / / June 11, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) will hold its Annual General and Special Meeting (AGM) virtually, on June 25, 2025, at 10:00 am ET. The AGM, including the live audio webcast and voting platform, can be accessed at . Registered shareholders and duly appointed proxyholders can vote at the AGM. Non-registered or beneficial shareholders who wish to vote at the AGM must appoint themselves as proxyholder by delivering a form of proxy and registering online at with Computershare Investor Services before 10:00 am ET, June 23, 2025. If you are not a registered shareholder with a control number or you have not appointed yourself a proxy ahead of the meeting, you will not be able to vote. However, you can still join the meeting as a guest. For more information, including a user guide with additional details on how to join the AGM, whether you are a registered shareholder, a non-registered shareholder, a beneficial shareholder, or a guest, visit A replay of the AGM will be available at About BlackBerry BlackBerry (NYSE:BB)(TSX:BB) provides enterprises and governments the intelligent software and services that power the world around us. Based in Waterloo, Ontario, the company's high-performance foundational software enables major automakers and industrial giants alike to unlock transformative applications, drive new revenue streams and launch innovative business models, all without sacrificing safety, security, and reliability. With a deep heritage in Secure Communications, BlackBerry delivers operational resiliency with a comprehensive, highly secure, and extensively certified portfolio for mobile fortification, mission-critical communications, and critical events management. For more information, visit and follow @BlackBerry. Investor Contact: BlackBerry Investor Relations+1 (519) 888-7465investorrelations@ Media Contact: BlackBerry Media Relations+1 (519) 597-7273mediarelations@ SOURCE: BlackBerry View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
11-06-2025
- Business
- Yahoo
CaNickel Announces Shareholder Approval of All Resolutions at AGSM; to Delist from the TSXV on June 26, 2025
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - CaNickel Mining Limited (TSXV: CML) ("CaNickel" or the "Company") announces that, further to its press release on May 7, 2025, shareholders have approved all resolutions put forth at the Company's Annual General and Special Meeting ("AGSM"), which was held in Vancouver, BC, on June 11, 2025. This included the passing of an Ordinary Resolution, by a majority of the minority shareholders of the Company, authorizing the voluntary delisting of the Company's common shares from the TSX Venture Exchange ("TSXV"). The Company expects the delisting to occur at the close of business on Thursday, June 26, 2025, subject to final TSXV approval. At the AGSM, a total of 29,212,122 common shares were represented by proxy, representing 77.86% of the Company's outstanding common shares. The final voting results of the meeting are set out below. Election of Directors Shareholders have elected Wenfeng Liu, Shirley Anthony and James Dai to serve as directors until the next annual meeting of shareholders, or until their respective successors are elected or appointed. Myles Gao, Lorne Waldman, Kevin Zhu and Weiliang Wang did not stand for renomination to the Board. The Company extends its sincere gratitude to all outgoing directors for their invaluable contributions and wishes them continued success in their current and future endeavors. The table below sets forth the vote of the shareholders at the AGSM with respect to the election of directors: Nominee For Abstained Wenfeng Liu 99.842% 0.158% Shirley Anthony 99.817% 0.183% James Dai 99.809% 0.191% Appointment of Auditor Shareholders have approved the appointment of Baker Tilly WM LLP as auditor of the Company to hold office until the close of the next annual meeting of shareholders at such remuneration as may be fixed by the directors of the company. The table below sets forth the vote of the shareholders at the AGSM with respect to the appointment of the auditor: Appointment of Auditor For Abstained Baker Tilly WM LLP 99.960% 0.040% Voluntary TSX Venture Exchange Delisting An ordinary resolution has been approved by a majority of the minority shareholders of the Company authorizing the voluntary delisting of the Company's common shares from the TSXV. Excluding directors, officers, promoters, and shareholders holding 10% or more of the Company's common shares and their Associates and Affiliates ("Non-Arm's Length Parties" as defined in TSXV Policy 1.1.), a total of 15,043,782 shares were voted by disinterested shareholders on the resolution and the table below sets forth the voting results: Ordinary Resolution For Against Approval of Voluntary Delisting from the TSXV 99.588% 0.412% Under TSXV policies, delisting of a listed company when the company does not have an alternative public market requires majority of minority approval, meaning that directors, officers, promoters, and shareholders holding 10% or more of the Company's common shares and Non-Arm's Length Parties were not permitted to vote. Also excluded from the vote were King Place Enterprises Limited, which holds 11,517,653 shares, as well as its affiliate company, Hebei Wenfeng Industrial Group, which holds 2,587,500 shares. The total number of shares that were excluded from voting on the resolution was 14,105,153, representing 37.6% of the total number of shares outstanding. With the passing of the resolution, along with Board approval of the delisting on April 22, 2025, the Company will proceed to finalize the process of voluntarily delisting from the TSXV. The delisting is expected to occur at the close of business on Thursday, June 26, 2025, subject to final TSXV approval. The Company will remain a reporting issuer in Canada and will continue to comply with its continuous disclosure obligations under applicable securities laws. ABOUT CANICKEL CaNickel Mining Limited is a Canadian junior mining company that currently owns the Bucko Lake Mine, currently on care and maintenance, near Wabowden, Manitoba. From 2009 to 2012, nearly 450,000 tonnes of mineralized material were mined to produce 6.9 million pounds of nickel before the mine was put on care and maintenance due to low nickel prices. Further information is available at or contact: Shirley AnthonyChief Executive OfficerPhone: 778-999-2771 CaNickel Mining LimitedSuite 720 - 320 Granville British Columbia Canada V6C 1S9 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
05-06-2025
- Business
- Yahoo
Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ("AGSM") to take place on Wednesday, June 11th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada. In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed. The corporate power point presentation and question and answer period will end at 6:30 pm ET. Zoom Meeting Link: ID: 871 7513 9183Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom. An archived version will be available on the website, the next business day, following the conference call. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPAChief Financial Officer X 224khachey@ To view the source version of this press release, please visit
